Table 2.
Univariate and multivariate Cox regression analyses for OS of patients (n=218)
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age | ||||
| >59 years vs ≤59 years | 1.190 (0.814-1.740) | 0.370 | ||
| Gender | ||||
| Male vs Female | 0.842 (0.541-1.311) | 0.447 | ||
| Histologic type | ||||
| Non-clear cell vs clear cell type |
1.367 (0.832-2.244) | 0.217 | ||
| Tumor nucleus grade | ||||
| 3+4 vs 2 | 1.366 (1.042-1.790) | 0.024 | 0.999 (0.649-1.539) | 0.997 |
| Initial TNM stage | ||||
| III+ IV vs I+ II | 1.463 (1.002-2.135) | 0.049 | 1.456 (0.956-2.217) | 0.080 |
| Tumor size | ||||
| Per 1cm increase | 1.196 (0.982-1.455) | 0.075 | ||
| Pulmonary metastasis | ||||
| Present vs Absent | 1.736 (1.149-2.622) | 0.009 | 1.464 (0.940-2.280) | 0.091 |
| Systemic therapy | ||||
| Sorafenib vs Sunitinib | 1.045 (0.696-1.568) | 0.832 | ||
| Tumor necrosis | ||||
| Present vs Absent | 1.339 (0.899-1.993) | 0.151 | ||
| Metastatic organ number | ||||
| ≥2 vs 1 | 1.091 (0.732-1.626) | 0.667 | ||
| tPD-L1 | ||||
| Positive vs Negative | 1.494 (1.011-2.210) | 0.044 | 0.874 (0.514-1.488) | 0.621 |
| sPD-L1 | ||||
| Positive vs Negative | 1.987 (1.336-2.954) | 0.001 | 1.740 (1.065-2.843) | 0.027 |
| Treg | ||||
| High vs Low | 1.573 (1.061-2.333) | 0.024 | 1.750 (1.067-2.870) | 0.027 |
| CD8 | ||||
| High vs Low | 0.543 (0.371-0.794) | 0.002 | 0.499 (0.316-0.790) | 0.003 |
| CD4 | ||||
| High vs Low | 0.626 (0.428-0.914) | 0.015 | 0.649 (0.404-1.043) | 0.074 |
| PD-1 | ||||
| High vs Low | 1.713 (1.151-2.548) | 0.008 | 1.840 (1.158-2.925) | 0.010 |
| IMDC | <0.001 | <0.001 | ||
| Favorable | 1.000 | 1.000 | ||
| Intermediate | 1.381 (0.761-2.507) | 1.599 (0.859-2.977) | ||
| Poor | 3.528 (1.828-6.810) | 3.995 (1.934-8.255) | ||
| IS | <0.001 | |||
| Low | 1.000 | |||
| Intermediate | 1.985 (1.275-3.093) | |||
| High | 3.061 (1.792-5.229) | |||
Abbreviations: tPD-L1,tumor cells PD-L1 expressions; sPD-L1, stromal immune cells PD-L1 expressions; CI, confidence interval; IMDC, International Metastatic Renal Cancer Database Consortium; OS, overall survival; IS, Immunoscore.